Nanomedicine in Cancer Therapy: Current Status and Advances

Dear Colleagues,

The scope and aim of a special issue on “Nanomedicine in Cancer Therapy: Current Status and Advances” would typically revolve around providing a comprehensive overview of the latest advancements, challenges, and potential applications of nanotechnology in the field of cancer treatment. Here’s a breakdown of what such a special issue might entail:

Nanomedicine: The special issue would cover various aspects of nanomedicine, focusing on the use of nanotechnology for diagnosis, treatment, and monitoring of cancer.
Cancer Therapy: It would explore different therapeutic strategies such as chemotherapy, immunotherapy, targeted therapy, and combination therapy, all of which leverage nanotechnology to improve efficacy and reduce side effects.
Current Status: The issue would provide an up-to-date assessment of the current state of research, including recent breakthroughs, clinical trials, and emerging trends.
Advances: Emphasis would be placed on highlighting recent advances in nanomedicine, including novel drug delivery systems, imaging techniques, biomaterials, and theranostic approaches.
Challenges and Opportunities: The special issue would address challenges hindering the translation of nanomedicine from the bench to the bedside, as well as opportunities for future research and development.
Knowledge Dissemination: The primary aim would be to disseminate cutting-edge research and knowledge in the field of nanomedicine and cancer therapy to a broad audience, including researchers, clinicians, policymakers, and industry professionals.
Critical Analysis: The special issue would critically evaluate the current state of the art, identify gaps in knowledge, and propose avenues for further investigation.
Clinical Translation: Another aim would be to facilitate the translation of promising nanomedicine-based cancer therapies from the laboratory to clinical practice by discussing regulatory considerations, safety profiles, and scalability issues.
Collaboration and Networking: By bringing together contributions from experts in academia, industry, and healthcare, the special issue would foster collaboration and networking among stakeholders with a shared interest in advancing cancer treatment through nanotechnology.

Overall, the special issue on “Nanomedicine in Cancer Therapy: Current Status and Advances” would serve as a comprehensive resource for researchers and practitioners seeking to stay abreast of the latest developments and breakthroughs in this rapidly evolving field.

Dr. Girum Getachew Demissie
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Functional Biomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.